Abbott Laboratories

ABT
Financial Analysis · Updated May 12, 2026 · Coverage 2026-Q2
Latest Q Revenue
$11.2B
Q1 2026 · +7.3% YoY
TTM ROIC
13.2%
FY2025 · NOPAT / Invested Capital (NOPAT = Adj. Operating Income × (1 - tax rate); Invested Capital = Total Assets - Cash - Non-interest-bearing liabilities) · WACC ~7.5% · Moat spread +5.7pp
Margin Profile
Gross 56.5%
Operating 23.5%
FCF 16%
FY2025
Net Debt
$27.0B
Cash $8.0B · Debt $35.0B · FY2025 post-Exact Sciences

Business Overview

ticker: ABT step: 01 generated: 2026-05-12 source: quick-research

Abbott Laboratories (ABT) — Business Overview

Business Description

Abbott Laboratories is a diversified healthcare company operating across four segments: Medical Devices (45% of revenue), Nutrition (22%), Diagnostics (20%), and Established Pharmaceuticals (13%). The portfolio anchored by FreeStyle Libre (#1 global continuous glucose monitor — $7B+ run rate growing 20%+) and structural heart franchise (MitraClip, TriClip, Amplatzer Amulet). The March 2026 close of the $20B+ Exact Sciences acquisition adds high-growth cancer diagnostics. Robert Ford is CEO.

Revenue Model

  • Medical Devices (~45% of revenue): Diabetes (FreeStyle Libre CGM + Lingo consumer biosensor), Cardiovascular (Coronary, Structural Heart, Heart Failure, Vascular), Neuromodulation, Rhythm Management (AVEIR leadless pacemakers, Volt PFA)
  • Nutrition (~22%): Pediatric (Similac, PediaSure), Adult (Ensure, Glucerna), International nutrition
  • Diagnostics (~20%): Core Lab (Alinity), Molecular (m2000, Alinity m), Rapid Diagnostics, Point of Care (post-Exact Sciences: cancer screening)
  • Established Pharmaceuticals (EPD, ~13%): Branded generics primarily in emerging markets (India, Latin America, China, Russia, etc.)

Products & Services

Medical Devices
  • FreeStyle Libre family: Libre 2 Plus, Libre 3 Plus, Libre 4 (under development), Lingo consumer wellness biosensor — #1 CGM globally
  • Cardiovascular: XIENCE coronary stents, MitraClip + TriClip (transcatheter heart valves), Amplatzer Amulet (LAA closure), Navitor, HeartMate (heart failure)
  • Rhythm Management: AVEIR leadless pacemakers (single + dual-chamber), Volt PFA (pulsed field ablation, FDA approved Dec 22, 2025)
  • Vascular: XIENCE PRO, Esprit BTK
  • Neuromodulation: Spinal cord stim, deep brain stim, dorsal root ganglion
Diagnostics
  • Alinity: Integrated lab platform
  • m2000 / Alinity m: Molecular (PCR)
  • Rapid Diagnostics: BinaxNOW, ID Now
  • Exact Sciences (March 2026): Cologuard (colorectal cancer screening), Oncotype DX
Nutrition
  • Pediatric: Similac infant formula, PediaSure, Pedialyte
  • Adult: Ensure, Glucerna, ZonePerfect
  • International nutrition (high growth in EM)
Established Pharmaceuticals
  • Branded generics in ~15 emerging markets
  • Cardiology, hepatology, gastroenterology, women's health franchises

Customer Base & Go-to-Market

  • Patients: Billions globally — Libre alone has ~6M users, Cologuard 4M+ tests annually
  • Physicians + Hospitals: Cardiologists, electrophysiologists, endocrinologists, OB-GYN, primary care
  • Pharmacies + retailers: Nutrition products through grocery + drug + Amazon
  • Public sector: WIC + global infant nutrition programs
  • Geographic mix: ~40% International, ~60% US

Competitive Position

Abbott has multiple #1 or #2 positions in major franchises: #1 in CGM (Libre vs Dexcom G7), #1 in heart valve replacement via MitraClip, #1 nutritional products company globally. Moats: (1) Libre cost-efficient CGM strategy (lower price + broader access vs Dexcom premium), (2) MitraClip first-mover advantage in TEER market, (3) AVEIR dual-chamber leadless pacemaker first to market, (4) Exact Sciences Cologuard franchise dominant in colorectal screening. Faces (1) Dexcom in CGM (especially G8/Stelo), (2) Boston Scientific in PFA + electrophysiology, (3) Medtronic broadly across devices.

Key Facts

  • Founded: 1888 (Wallace C. Abbott)
  • Headquarters: Abbott Park, IL
  • Employees: ~115,000
  • Exchange: NYSE
  • Sector / Industry: Health Care / Medical Devices + Diagnostics + Nutrition
  • Market Cap: ~$215B (May 2026)
  • CEO: Robert B. Ford (since 2020)
  • Dividend: $2.36 annual ($0.59 quarterly)
  • 52 consecutive years of dividend growth (Dividend King)
  • Major M&A: Exact Sciences $20B+ (closed March 2026); legacy: AbbVie spin-off 2013, St. Jude Medical $25B 2017

Financial Snapshot

ticker: ABT step: 04 generated: 2026-05-12 source: quick-research

Abbott Laboratories (ABT) — Financial Snapshot

Income Statement Summary

Metric FY2023 FY2024 FY2025 YoY
Revenue $40.1B $42.0B $44.5B +6%
Organic Sales Growth flat +7.1% +8%
Gross Margin 55.5% 56.0% 56.5% +50bps
Adj. Operating Margin 20.2% 22.6% 23.5% +90bps
Adj. Net Income $7.6B $8.1B $9.0B +11%
Adj. EPS $4.44 $4.67 $5.18 +11%
Free Cash Flow $6.4B $6.5B $7.2B +11%

Segment Revenue (FY2025)

Segment Revenue YoY Growth
Medical Devices $20.2B +9% (Diabetes +18%, CV +11%)
Diagnostics $9.0B flat (COVID drag)
Nutrition $8.5B -2% (volume weakness)
Established Pharmaceuticals $5.7B +9%

Q1 2026 Highlights

Metric Q1 2026
Medical Devices Growth +8.5%
Diabetes Care (Libre) $2.08B (annualizes to $8.3B)
Continuous Glucose Monitoring $2B+ (+7.5%) — affected by recall
Rhythm Management +17% (AVEIR)
Diagnostics +3% Core Lab
Nutrition Recovering from -8.9% in Q4 2025

Key Product Metrics

Metric Value
FreeStyle Libre 2025 revenue ~$7B
2028 Libre target $10B (~10% annual growth required)
Lingo consumer biosensor Launched 2024
Volt PFA approval December 22, 2025 (FDA)
Exact Sciences incremental revenue 2026 ~$3B

Cash Flow & Balance Sheet (FY2025)

Metric Value
Operating Cash Flow ~$8.5B
Capital Expenditures ~$1.5B
Free Cash Flow ~$7.2B
Cash & Equivalents ~$8B
Total Debt ~$15B pre-Exact Sciences; ~$35B post-Exact Sciences (+$20B for acquisition)

Key Ratios (approximate, May 2026)

  • P/E (forward): ~24x | EV/EBITDA: ~17x | Dividend Yield: ~2.0%
  • ROIC: ~14% (will dip on Exact Sciences integration before accretion)
  • FCF Margin: ~16%
  • Net Debt/EBITDA: ~3x post-Exact Sciences (elevated near-term)

Growth Profile

FY26 sales outlook: 6.5-7.5% comparable growth. Medical Devices is the primary growth engine (especially Libre + Volt PFA + AVEIR). Q1 2026 saw Libre annualizing to $8.3B run rate. Exact Sciences ($3B incremental revenue 2026, growing high-teens) adds to Diagnostics. Bear-case overhang: FreeStyle Libre 3/3 Plus recall (3M units, FDA Class I, 860 serious injuries + 7 deaths) plus nutrition softness.

Forward Estimates

  • FY2026E Revenue: ~$50B (incl. Exact Sciences full year)
  • FY2026E Adj EPS: $5.05-5.25 (mgmt guide; +6-8%)
  • FY2027E EPS: ~$5.85 (+12-15%)
  • FY2028E Libre revenue target: $10B+ (vs $7B in 2025)

Capital Return

  • Dividend $2.36 annual (~$4B paid)
  • 52 consecutive years of dividend growth (Dividend King)
  • Buybacks: ~$2-3B annual run rate, moderated post-Exact Sciences debt paydown priority
  • Total return: ~3-4% combined yield + 10%+ EPS growth

Deeper Financial Analysis

The fundamental tier adds 9 additional research dimensions for $ABT.

Revenue Breakdown
Segment revenue, geographic mix, product-line contribution margins, and cohort dynamics.
Financial Trends
Quarter-over-quarter momentum, leading indicators, and inflection point analysis.
Balance Sheet
Debt structure, liquidity runway, dilution risk, and working capital dynamics.
Capital Allocation
Buyback cadence, M&A appetite, dividend policy, and reinvestment priorities.
Returns on Capital (ROIC)
Multi-year ROIC vs. WACC, marginal returns on reinvestment, sales-to-invested-capital efficiency, and moat spread.
GET /api/v1/research/ABT/fundamental$1.00 · Bearer token required
Markdown: /stocks/abt/financials/md · → thesis · → memo